All News

This feels like an excellent starting point for Tuesday's ORAL Surveillance malignancy discussion. RWE Cohort: HR 1.01 (0.83-1.22) RCT-dup Cohort: HR 1.19 (0.86-1.64) ORAL Surveillance: HR 1.48 (1.04-2.09) Interesting day 4 ahead! great talk @SeoyoungCKim #ACR21 7S413 @RheumNow https://t.co/YSau21goMr
David Liew drdavidliew ( View Tweet)
Does concomitant SJS affect tx effectiveness in RA? Abst#0839 suggest yes! ➡️RA+SjS have an inferior response to TNFi than RA patients w/o SjS BUT, RA/SJS pts w/ longer RA dz duration & ↑ DAS28 + HAQ-scores. What's your clinical experience with this? #ACR21 @Rheumnow https://t.co/TIc3raMOSJ
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
If obvious dermatomyositis, you don’t need EMG for dx but may use for severity of involvement or if failing Rx or r/o steroid myopathy. For ?polymyositis ALWAYS do bx and often do EMG as broad differential #ACR21 @RheumNow https://t.co/L1xu3OuRYJ

Links:

Janet Pope Janetbirdope ( View Tweet)

RheumNow’s expanded coverage of #ACR21 is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

A worthwhile point: despite historic concerns, in the modern era TNFi can used safely & well in HIV pts 18y follow-up, all pts high CD4 (their starting criteria: CD4>200, VL <60,000) no reported opportunistic infx good arthritis response #ACR21 ABST0965 @RheumNow @CCalabreseDO https://t.co/5pbRg63ubr
David Liew drdavidliew ( View Tweet)
Abst#0572: In US veterans w/ RA followed for 17 yrs, several cytokines+chemokines ⭐️Associated w/ ↑ risk of incident MACE independent of typical CVD RF & RA activity & ⭐️Predicted MACE even if in LDA/remission WOW! We need to do better @ CVD risk strat! #ACRBest @RheumNow https://t.co/J74rRa9EQE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR21 #Abstr0865 It’s time for T2T to achieve LLDAS in #lupus. In a study of N=2040 pts, mortality was 2.3% mainly due to infection. Remission off steroid was the best but only met in 14%. LLDAS-50 achieved in 48% pts and ⬇️mortality by 56% @RheumNow https://t.co/CddqMuFIOM https://t.co/g346Cbybep

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Join the @RheumNow faculty tonight for a recap of Day 2 at #ACR21 ⏰19:00 ET ⏰Midnight GMT- I promise to be well-caffeinated to present my many highlights from today! 😄 📺Register via the Zoom link below or watch on Youtube https://t.co/6HIQGR5T8z

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

beautifully chaired by @cappelliMD also elegant talk on 'M-triad' by the always articulate @lovetolearn27, made me think about my pt on the ward right now! #ACR21 @RheumNow @CCalabreseDO @LCalabreseDO @got_rheum @MarieKostine @lexmeara @ReidMDMPH @NilashaGhosh @RheumDr_Nina https://t.co/2iu6zWp8Ge
David Liew drdavidliew ( View Tweet)
*️⃣CT-P13=1st monoclonal biosimilar to infliximab (IFX) ⭐️ReFLECT: 1370 French pts (142 RA, 411 axSpA, 96 PsA) →2 groups: IFX-naïve starting CT-P vs switching from IFX to CT-P *️⃣CT-P13 induced improvement in IFX-naïve & maintained dz in pts switched Abst#0817 #ACR21 @RheumNow https://t.co/bASmGvhuIS
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Great talk by @saadhealth #ACR21 & interesting to compare myocarditis irAEs to inflamm arthritis irAEs: similar: - importance of confirming dx well - cautious adoption steroid-sparing Rx different: - clear benefit hard/early Rx - dx metrics aided by tech #ACR21 7S404 @RheumNow https://t.co/mFjM3ZlZaP
David Liew drdavidliew ( View Tweet)
Catching up with #ACR21 content?🧐 Please read my article on updates of safety and effectiveness of #COVID19 vaccines in people with #lupus @RheumNow https://t.co/pru9dTH4z7

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

⭐️2 polyunsaturated fatty acid lipid mediator profiles are significantly associated w/ incident inflammatory arthritis in ACPA+ pts ➡️If validated, this would be of great utility in determining which pts w/ pre-clinical sero+ should be treated! Abst#0590 at #ACR21 @RheumNow https://t.co/KGEwiY6G2Q
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients Rubbert-Roth and colleagues found: - RA patients developed anti-S1 antibodies slower and lower compared to controls - Reduced titers among Abatacept & JAKi users #ACR21 @RheumNow https://t.co/sXW8d53O8m
Akhil Sood MD AkhilSoodMD ( View Tweet)
Rheumatologists and Health Professionals: Join us tonight for RheumNow's #ACR21 Daily Recap at 7pm Eastern time . Register via the Zoom link below. https://t.co/sxQuP28APX Or visit our YouTube channel-RheumNow. https://t.co/sohrPTB16S https://t.co/LXWaBFOdHO

Links:

Dr. John Cush RheumNow ( View Tweet)
Post-Hoc of ASCORE trial: ➡️RA w/ mod-high dz on SQ ABAtacept as 1st line tx w/ better retention vs receiving it as 2nd line tx independent of b/l duration of dz ➤Do you use ABA as 1st line treatment for RA, when/if insurance allows? Comment below! Abst#0816 #ACR21 @RheumNow https://t.co/TRJga4OfiW
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Cathepsin K - has some promise in Knee OA - now going to Phase 3 @RheumNow https://t.co/exUFqcCJy1
Bella Mehta bella_mehta ( View Tweet)
NORD-STAR Trial: outcomes in tx-naïve, early RA pts after 48w of csDMARDs+GC vs bDMARD (ABAtacept, CerToliZumab, or ToCiluZumab)+MTX ➡️ Superior CDAI remission rates w/ ABA+MTX & CZP+MTX but not TCZ+MTX vs csDMARD+GC ➡️Imaging progression low in all Abst#0825 #ACR21 @RheumNow https://t.co/QaFIF4WNEG
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR21 #Abstr0871 📢Argument against HCQ<5mg/kg dose from cardiac perspective in #lupus. A retrospective study N=296 pts, 13% developed CV events.⬇️28% in risk of heart failure, arrhythmia/cardiac death per mg/kg of HCQ in non-smokers @RheumNow #ACRBest https://t.co/6ssd2159R1 https://t.co/tllPWLnFFj

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
@SteliosTomaras @RichardPAConway @drhectorchinoy @RheumNow EMG/NCS can help uncover various neurological disorders including muscle dystrophies. Obviously it depends on center and expertise. Both MRI and EMG are useful and have different complementary utilities in Myositis. Many centers are not able to perform or interpret MRI reliably.

Rohit Aggarwal docrota ( View Tweet)

×